Author:
Corrao Giovanni,Biffi Annalisa,Porcu Gloria,Ronco Raffaella,Adami Giovanni,Alvaro Rosaria,Bogini Riccardo,Caputi Achille Patrizio,Cianferotti Luisella,Frediani Bruno,Gatti Davide,Gonnelli Stefano,Iolascon Giovanni,Lenzi Andrea,Leone Salvatore,Michieli Raffaella,Migliaccio Silvia,Nicoletti Tiziana,Paoletta Marco,Pennini Annalisa,Piccirilli Eleonora,Rossini Maurizio,Tarantino Umberto,Brandi Maria Luisa
Abstract
BackgroundFragility fractures are a major public health concern owing to their worrying and growing burden and their onerous burden upon health systems. There is now a substantial body of evidence that individuals who have already suffered a fragility fracture are at a greater risk for further fractures, thus suggesting the potential for secondary prevention in this field.PurposeThis guideline aims to provide evidence-based recommendations for recognizing, stratifying the risk, treating, and managing patients with fragility fracture. This is a summary version of the full Italian guideline.MethodsThe Italian Fragility Fracture Team appointed by the Italian National Health Institute was employed from January 2020 to February 2021 to (i) identify previously published systematic reviews and guidelines on the field, (ii) formulate relevant clinical questions, (iii) systematically review literature and summarize evidence, (iv) draft the Evidence to Decision Framework, and (v) formulate recommendations.ResultsOverall, 351 original papers were included in our systematic review to answer six clinical questions. Recommendations were categorized into issues concerning (i) frailty recognition as the cause of bone fracture, (ii) (re)fracture risk assessment, for prioritizing interventions, and (iii) treatment and management of patients experiencing fragility fractures. Six recommendations were overall developed, of which one, four, and one were of high, moderate, and low quality, respectively.ConclusionsThe current guidelines provide guidance to support individualized management of patients experiencing non-traumatic bone fracture to benefit from secondary prevention of (re)fracture. Although our recommendations are based on the best available evidence, questionable quality evidence is still available for some relevant clinical questions, so future research has the potential to reduce uncertainty about the effects of intervention and the reasons for doing so at a reasonable cost.
Subject
Endocrinology, Diabetes and Metabolism
Reference399 articles.
1. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures;Davis;Health Technol Assess,2016
2. GenevaAssessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series, no. 8431994
3. Hip fractures in the elderly: a world-wide projection;Cooper;Osteoporos Int,1992
4. Broken bones, broken lives – the fragility fracture crisis in six European countries2018
5. Glossary
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献